Literature DB >> 11403267

Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients.

F Formiga1, J F Meco, X Pinto, J Jacob, I Moga, R Pujol.   

Abstract

The purpose of this study was to assess the prevalence of dyslipoproteinemia and to analyze the clinical variables that are associated with it in a sample of premenopausal systemic lupus erythematosus (SLE) patients. We studied 53 premenopausal (34.5 y) SLE outpatients and 45 controls. Clinical variables studied included patient age, weight, height, body mass index (BMI), age at disease onset, disease duration, clinical activity of SLE, renal involvement and drug therapy. Total cholesterol (TC), high- and low-density lipoprotein cholesterol (HDL-C and LDL-C), and triglycerides were measured using standard enzymatic techniques. Apolipoproteins (apo) A-I and B were determined by radial immunodiffusion. Twenty-nine patients (55%) and 14 controls (30%) had dyslipoproteinemia. An increase in TC, triglycerides, HDL3-C, apo A-I and apo B, and a decrease in HDL2-C and HDL-C/TC index was found in SLE patients in comparison with controls. TC (P = 0.007), apo B (P = 0.02), LDL-C (P = 0.03) and triglycerides (P = 0.0001) were significantly correlated with proteinuria. Patients on prednisone therapy had higher triglycerides levels (P = 0.03) than untreated patients. TC (P = 0.01), LDL-C (P = 0.006) and triglycerides (P = 0.04) were also correlated with the dose of prednisone. Dyslipoproteinemia is a common feature in adult SLE premenopausal patients which is characterized by an increase in TC, triglycerides and apo B, and an abnormal distribution of HDL subclasses. Corticosteroid therapy and proteinuria are the best predictors of dyslipoproteinemia in these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403267     DOI: 10.1191/096120301669070811

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

1.  Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies.

Authors:  Sara Kashef; Mohammad Mehdi Ghaedian; Akbar Rajaee; Abbas Ghaderi
Journal:  Rheumatol Int       Date:  2006-08-30       Impact factor: 2.631

2.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

Review 3.  mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.

Authors:  Andras Perl
Journal:  Ann N Y Acad Sci       Date:  2015-04-23       Impact factor: 5.691

4.  Sequential evaluation of clinical and laboratory changes amongst children suffering from lupus nephritis during intermittent intravenous cyclophosphamide therapy.

Authors:  Shih-Jung Chiu; Liang-Shiou Ou; Tien-Lung Tsai; Iou-Jih Hung; Jing-Long Huang
Journal:  Clin Rheumatol       Date:  2005-11-10       Impact factor: 2.980

Review 5.  Dyslipoproteinemia and premature atherosclerosis in pediatric systemic lupus erythematosus.

Authors:  Laura E Schanberg; Christy Sandborg
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

6.  Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients.

Authors:  Claudia R L Cardoso; Flávio V Signorelli; Jose A Papi; Gil F Salles
Journal:  Rheumatol Int       Date:  2007-09-04       Impact factor: 2.631

7.  Elevation of fasting insulin and its association with cardiovascular disease risk in women with systemic lupus erythematosus.

Authors:  Tim K Tso; Wen-Nan Huang
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

8.  Dyslipidaemia in rheumatological autoimmune diseases.

Authors:  Tracey E Toms; Vasileios F Panoulas; George D Kitas
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

Review 9.  High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy.

Authors:  Sang Yeop Kim; Minzhi Yu; Emily E Morin; Jukyung Kang; Mariana J Kaplan; Anna Schwendeman
Journal:  Arthritis Rheumatol       Date:  2019-11-26       Impact factor: 10.995

10.  Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.

Authors:  April Bingham; Gulnara Mamyrova; Kristina I Rother; Elif Oral; Elaine Cochran; Ahalya Premkumar; David Kleiner; Laura James-Newton; Ira N Targoff; Janardan P Pandey; Danielle Mercatante Carrick; Nancy Sebring; Terrance P O'Hanlon; Maria Ruiz-Hidalgo; Maria Turner; Leslie B Gordon; Jorge Laborda; Steven R Bauer; Perry J Blackshear; Lisa Imundo; Frederick W Miller; Lisa G Rider
Journal:  Medicine (Baltimore)       Date:  2008-03       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.